tafamidis; tafamidis meglumine (Vyndaqel. Vyndamax)
Jump to navigation
Jump to search
Indications
Dosage
- 20-80 mg QD
Mechanism of action
- tafamidis binds to transthyretin & stabilizes it, & inhibits its deposition as amyloid
- lowers all-cause mortality (30% vs 43%, RR=0.70)
- lessened decline in 6-minute walk test
More general terms
Additional terms
References
- ↑ Maurer MS, Schwartz JH, Gundapaneni B et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018 Aug 27; PMID: https://www.ncbi.nlm.nih.gov/pubmed/30145929 Free full text https://www.nejm.org/doi/10.1056/NEJMoa1805689
Quarta CC, Solomon SD. Stabilizing transthyretin to treat ATTR cardiomyopathy. N Engl J Med 2018 Aug 27 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30145933 Free Article https://www.nejm.org/doi/10.1056/NEJMe1810074